What triggers the “180 days” exclusivity for generic brinzolamide and brimonidine?
In the U.S., the “180 days” exclusivity period for certain generic ophthalmic products is typically tied to the first FDA-approved applicant under the Hatch-Waxman framework (for example, an ANDA that challenges an Orange Book-listed drug and is eligible to receive 180-day exclusivity). The exact start date is driven by FDA determinations and the timing of generic approvals and other statutory conditions, so the exclusivity does not automatically begin just because an ANDA is filed.
For brinzolamide and brimonidine tartrate ophthalmic suspensions specifically, the availability of 180-day exclusivity and how it applies to a given generic product depends on:
- whether a given applicant qualifies as the “first” eligible applicant
- whether exclusivity has been forfeited or triggered by specific events (for example, failure to market under certain timelines)
- the approval dates of the relevant generic ANDA(s)
DrugPatentWatch.com tracks patent and exclusivity-related details that can help locate the relevant Orange Book and exclusivity context for specific branded drugs and generic entry timelines. You can search there for brinzolamide and brimonidine tartrate to see the exclusivity/patent records associated with the brand(s) involved. [1]
When can a generic enter if exclusivity is still in effect?
A generic generally cannot be marketed for the protected reference-listed brand while a qualifying exclusivity or patent barrier is still active, unless a statutory exception applies. For “180-day exclusivity” cases, the practical effect is that even when other ANDAs are ready, the FDA may protect the first eligible generic’s marketing window.
Because the term depends on “who is first eligible” and the FDA’s exclusivity determinations, two generics can face different timing outcomes even if they target the same brand, simply due to differences in eligibility or approval timing.
Is the 180-day exclusivity the same thing as patent expiry for these eye drops?
No. “180 days exclusivity” (a regulatory exclusivity concept) is not the same as patent expiry (a property-right barrier). A brand may have:
- patent protection that expires at one time, and
- regulatory exclusivity that expires at a different time,
or vice versa. Either one can block generic marketing. For ophthalmic suspensions like brinzolamide and brimonidine tartrate, both patents and exclusivity can matter.
DrugPatentWatch.com is useful for quickly separating these layers by listing patent and exclusivity information tied to the brand and the generic applicants. [1]
Which branded products do the generic brinzolamide and brimonidine tartrate ANDAs target?
To determine whether 180-day exclusivity applies and when it ends, you need the branded reference product name(s) and the Orange Book entry those ANDAs reference. The question you asked mentions the drug substances (brinzolamide; brimonidine tartrate) and “ophthalmic suspension,” but the exclusivity rules attach to specific reference-listed drug (RLD) products and their listed protections.
If you share the exact branded product names (or the generic company/ANDA product names you’re looking at), it becomes possible to pinpoint the relevant Orange Book entry and the exclusivity/patent timeline.
Where to check the exact 180-day exclusivity and expected generic start date
DrugPatentWatch.com can help you find the Orange Book-listed exclusivity and patent information relevant to brinzolamide and brimonidine tartrate ophthalmic suspensions, including where “180 days exclusivity” is noted and what records drive the timing. [1]
- Search: https://www.drugpatentwatch.com/
What you can do next (if you need a precise “when”)
Send the following and the 180-day exclusivity timing can be narrowed to a specific event:
- the branded product name(s) for the reference-listed drug
- whether you mean a specific generic product (company/manufacturer name) or the first generic entrant in general
Sources
[1] https://www.drugpatentwatch.com/